A Phase 1 Dose‐Escalation, Food Effect, and Drug–Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR‐1505, in Healthy Volunteers

Documenti analoghi

• A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)‐Hydroxynorketamine in Healthy Volunteers
  di: Shruti M. Raja, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, Pharmacodynamics and Bioavailability of ACM‐001.1 ( S ‐Pindolol Benzoate) in Healthy Volunteers
  di: Frank Misselwitz, et al.
  Pubblicazione: (2024)
• 444 | A PHASE 1 STUDY OF SGR‐1505, AN ORAL, POTENT MALT1 INHIBITOR FOR R/R B‐CELL MALIGNANCIES, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
  di: V. Musteata, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
  di: Pamela Navarro‐Gonzales, et al.
  Pubblicazione: (2024)
• Intravenous Ganaxolone: Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability in Healthy Adults
  di: Maciej Gasior, et al.
  Pubblicazione: (2024)